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ABSTRACT
Background: Pancreatic cancer is often associated with cachexia. It had been reported that
eicosapentaenoic acid (EPA) improve cachexia. This study aimed to evaluate the efficacy and
safety of gemcitabine with an EPA-enriched oral supplement in patients with advanced pancreatic
cancer.
Methods: This open-label phase II study consisted of patients (pts) who were randomly
categorized into the EPA group (1,000mg/m2 gemcitabine was administered on day 1, 8,
and 15, every 4weeks while an EPA-enriched oral supplement (prosureVR , EPA 1.056mg per
pack) was taken daily at the maximum of two packs or the gemcitabine monotherapy
group with an allocation ratio of 2:1. The primary endpoint was the evaluation of the 1-year
survival estimating 10% addition.
Results: Randomized 68 pts were examined (EPA: 45, gemcitabine: 23). The 1-year survival prob-
ability of the EPA group was 35% while the gemcitabine group was 19%. The median survival times
were 8.2 and 9.7mo, respectively. The hazard ratio for EPA group was 0.79 [95% CI 0.46–1.37];
(P¼ 0.40). The toxicities were mild and insignificant in both groups. More beneficial effects of EPA
in survival were observed in men, pancreatic body-tail and low C-reactive protein patients.
Conclusion: An EPA-enriched oral supplement may be effective in advanced pancre-
atic cancer.
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Introduction
Pancreatic cancer is eighth leading cause of cancer death
with approximately 35,000 patients (1). Gemcitabine has
been the standard chemotherapy treatment in advanced
pancreatic cancer (PC) since 1997 (2). Recently,
FOLFIRINOX and gemcitabineþnab-paclitaxel has
become the standard chemotherapy treatment (3, 4).
However, the prognosis of PC is still dismal. PC often
has a cachexia (5). This is a metabolic alteration that
depends on pro-inflammatory mediators, such as IL-6,
TNF, and TWEAK, and tumor-derived catabolic factors,
such as activins and myostatin, and serotonin, which
causes appetite loss and decrease of body weight (6–8).
Such condition is one of the reasons of chemo-resistance
in PC. Although the prevention of cachexia is important
in performing chemotherapy, conventional nutritional
support including oral supplementation was not enough
to improve cachexia in the past (9, 10).
Eicosapentaenoic acid (EPA), an n-3 fatty acid
(omega-3), has shown an anticachectic effect in animal
model (11). These effects are related to the inhibition of
PIF and downregulation of proinflammatory cytokine
production. Moreover, additional protein and energy are
required in body synthesis. Oral nutritional supplement
including high protein and energy with EPA showed
weight gain and improved quality of life (6). On the other
hand, the effect of chemotherapy and EPA is not widely
known although it had been reported to improve
response rates (RR) in non-small cell lung cancer (12).
This time we aimed to examine the effect of an EPA-
enriched oral supplement with gemcitabine compared
with gemcitabine monotherapy in advanced PC.
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This multicenter, open-labeled, randomized phase II
study was conducted at two centers in compliance with
the Declaration of Helsinki and Good Clinical Practice
guidelines. The study protocol was approved by the eth-
ics committee or institutional review board of each par-
ticipating center. All patients provided written informed
consent before study entry. This study is registered with
the UMIN000003658. The department of Biostatistics
and Epidemiology in Yokohama City University moni-
tored patient safety, adverse events, and the progress of
the trial.
Patients
The eligibility criteria for inclusion were as follows: clin-
ical diagnosis of PC; unresectable or recurrent disease;
over 20 years of age; histologically or cytologically con-
firmed diagnosis of adenocarcinoma; ability to maintain
sufficient food intake with greater than two-thirds of
the normal intake as judged by interview; an Eastern
Cooperative Oncology Group performance status
(ECOG PS) of 0, 1/2, and adequate organ functions
such as leucocyte count  3,000 ⁄mm3; neutrophil count
 1,500⁄ mm3; hemoglobin level 9.0 g⁄ dL; platelet
count  100,000⁄mm3; aspartate aminotransferase and
alanine aminotransferase concentrations 100 IU⁄ L
(150 IU⁄L in patients with biliary drainage); total bili-
rubin level  2mg⁄dL (3mg⁄dL in patients with biliary
drainage); creatinine concentration  1.5mg⁄ dL;
Patients had no serious comorbidities. Patients with
interstitial pneumonia, lung fibrosis, or watery diarrhea
were excluded.
Randomization
After confirming eligibility, patients were randomly
assigned in a 2:1 ratio to receive gemcitabine mono-
therapy (gemcitabine group) or gemcitabine with an
EPA-enriched oral supplement (EPA group). Random
assignment was carried out centrally at the data cen-
ter, using the minimization method with institution,
the UICC stage (III vs. IV, recurrence), and ECOG PS
(0, 1, vs. 2) as allocation factors. The randomization
sequence was generated by the department of
Biostatistics and Epidemiology in Yokohama City
University, using a validated computer system blinded
from investigators. Both the investigators and patients
were aware of the assigned treatment.
Treatment
Gemcitabine 1,000mg/m2 was infused on day 1, 8, and
15 every 4weeks. The EPA-enriched oral supplement
(prosureVR , EPA 1.056 g per pack, Abbott, IL, USA) was
administered maximum two packs every day. In
patients who had grade four leucopenia or neutropenia,
grade four thrombocytopenia or grade three thrombo-
cytopenia requiring transfusion and grade three nonhe-
matologic toxicity, the dose of gemcitabine was reduced
in steps of 200mg/m2 until 600mg/m2 from the next
treatment cycle. If patients experienced grade three
diarrhea or the grade three adverse events related to
the EPA-enriched oral supplement, it was reduced to
one pack. And patients were allowed to reduce the vol-
ume of supplements dependent on their appetite.
Treatment was continued until disease progression,
unacceptable toxic effects, or the withdrawal of consent.
Assessments
Physical examinations, complete blood counts, and
biochemical tests were performed at least on day 1, 8,
and 15 every 4weeks. Thereafter all adverse events
were evaluated according to the National Cancer
Institute Common Terminology Criteria for Adverse
Events (version 4.0). CT or MRI was performed every
6weeks until disease progression. Response and dis-
ease progression were assessed by the attending physi-
cians and according to RECIST version 1.1. Data on
patients in whom treatment had been discontinued
before disease progression were censored on the last
day of tumor assessment (loss of events).
Study Objectives and Endpoints
The primary endpoint was 1-year survival defined as
the time from randomization. Secondary endpoints
were progression-free survival (PFS), defined as the
time from randomization to disease progression or
death from any cause, RR, body weight change, per-
formance status change, and adverse events.
Statistical Analysis
This study adopted selection design (13), in that the
regimen with a higher 1-year survival would be selected.
The sample size was determined as follows using
Simon’s selection design. We assumed that the 1-year
survival for one regimen would be 25% and that it
would be higher than 40% for the other regimen. Under
these conditions, the sample size ensuring a probability
of at least 78% for correct selection of the more effective
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regimen with one-sided a¼ 0.25 was 63 patients with
an allocation ratio of 2:1. Because the anticipated drop-
out rate of 5% required the addition of more patients,
the total number of patients was set at 66. Overall sur-
vival and PFS were estimated by using the
Kaplan–Meier method, and curves were compared using
an unstratified log–rank test. Hazard ratios of treatment
effects were estimated by using the unstratified Cox
regression model. We carried out all the analyses based
on full analysis set using SAS version 9.2 (SAS Institute,
Cary, NC, USA). The full analysis set was defined as the
population of patients who were given the study treat-
ment at least once. Unless otherwise specified, two-sided
P-values for superiority were used.
Results
Patients
Between May 2010 and October 2011, a total of 68
patients were enrolled and eligible. Two patients in
the EPA group were discontinued before treatment
due to cerebral infarction and worsening of perform-
ance status. Sixty-six patients were included in the
analysis set as shown in Table 1.
Study Treatment
At the primary analysis, the protocol treatment con-
tinued in one patient (2.3%) in the EPA group. The
main reason for treatment discontinuation was disease
progression [39 patients (90.7%) in the EPA group,
and 21 patients (91.3%) in the gemcitabine group].
Two patients [4.4%] in the EPA group, and two
patients [8.7%] in the gemcitabine group discontinued
the study treatment because of treatment-related
adverse events, and one patient (2.2%) in the EPA
group discontinued treatment because of non-related
adverse events. Two patients (4.4%) in the EPA group
could not be recognized with the reason and timing
of treatment discontinuation. The mean volume of
oral supplement was 1.13 packs/day.
Progression-Free and Overall Survival
The median PFS was 4.30mo, (95% confidence inter-
val (CI), 2.8 to 6.5mo,) in the EPA group and
4.20mo, (95% CI, 1.4 to 7.2mo,) in the gemcitabine
group (Fig. 1A). EPA group did not decrease the risk
of disease progression (HR, 0.82; 95% CI, 0.49 to
1.38; P¼ 0.455).
The median OS was 8.2mo, (95% CI, 5.7 to
11.9mo,) in the EPA group and 9.7mo, (95% CI, 4.9
to 11.1mo,) in the gemcitabine group (HR, 0.79; 95%
CI, 0.460–1.3; P¼ 0.404; Fig. 1B). One-year survival
which was primary endpoint was 35% (95% CI, 21%
to 49%) in the EPA group and 19% (95% CI, 6% to
37%) in the gemcitabine group. In subgroup analyses
of OS, the effect of EPA was better in males than
Table 1. Patient characteristics.
EPA (N¼ 43) GEM (N¼ 23)
N (%) P-valuea
Age
Median [range] 68 [48–83] 69 [42–84] 0.962
Gender
Male 22 (51.2%) 17 (73.9%) 0.114
Female 21 (48.8%) 6 (26.1%)
PS
0 23 (53.5%) 13 (56.5%) 1.000
1 18 (41.9%) 9 (39.1%)
2 2 (4.7%) 1 (4.3%)
Body weight
Median [range] 53.0 [28.8–73.8] 55.2 [43.3–72.8] 0.282
CA19-9
Median [range] 816.0 [8.0–558100.0] 579.0 [58.2–2961100.0] 0.341
Stage
III 9 (20.9%) 5 (21.7%) 1.000
IV, recurrence 34 (79.1%) 18 (78.3%)
Pancreatic resection
No 40 (93.0%) 22 (95.7%) 1.000
Yes 3 (7.0%) 1 (4.3%)
Location
Head 23 (53.5%) 12 (52.2%) 1.000
Body to tail 20 (46.5%) 11 (47.8%)
CRP
Median [range] 0.65 [0.04–7.18] 0.57 [0.03–2.82] 0.165
Albumin
Median [range] 3.8 [3.0–4.5] 3.8 [3.5–4.9] 0.165
ECOG PS: Eastern Cooperative Oncology Group performance status.
aP-values were calculated with Fisher’s exact test (F) or t-test (t).
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females (Fig. 2), in pancreas body-tail than head (Fig.
3A,B), and in patients of low C-reactive protein
(CRP) than those of high CRP (divided into 0.61mg/
dl; Fig. 4A,B).
Response to Therapy
The RR was 4.7% (95% CI, 0.6% to 15.8%) in the
EPA group and 8.7% (95% CI, 1.1% to 28.0%) in the
gemcitabine group (P¼ 0.606; Table 2). The DCR was
67.4% (95% CI, 51.5% to 80.9%) in the EPA group
and 65.2% (95% CI, 42.7% to 83.6%) in the gemcita-
bine group (P¼ 1.000; Table 2).
Post-Protocol Treatment (Second-Line
Chemotherapy)
Post-protocol treatment was given to 35 patients
(81.4%) in the EPA group and 17 patients (73.9%) in
the gemcitabine group. Most patients received S-1
monotherapy in both groups. Median CRP value was
0.73mg/dl in the EPA group and 1.00mg/dl in the
Figure 1. A: Progression-free survival. B: Overall survival.
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gemcitabine group in the timing of treatment discon-
tinuation. Median albumin value was 3.7mg/dl in the
EPA group and 3.5mg/dl in the gemcitabine group in
the timing of treatment discontinuation. Twelve
patients (27.9%) in the EPA group and two patients
(8.7%) in the gemcitabine group (P¼ 0.113) had low
CRP value (1.0mg/dl) and high albumin value
(4.0mg/dl) in the timing of treatment
discontinuation.
Safety
It shows the adverse events recorded within 6mo,
after randomization. The major grade 3 or four
adverse events had incidences of  5% were neutro-
penia (30.2% in the EPA group vs. 21.7% in the gem-
citabine group), leukopenia (20.9% vs. 13.0%), anemia
(14.0% vs. 8.7%), thrombocytopenia (9.3% vs. 8.7%),
hyponatremia (9.3% vs. 4.3%), decreased appetite
(7.0% vs. 0.0%), nausea (11.6% vs. 0.0%), and infec-
tion (mainly cholangitis; 7.0% vs. 13.0%). CRP eleva-
tion (11.6% vs. 39.1%) of all grades were significantly
higher in the gemcitabine group (Table 3). Serious
adverse events related to the protocol treatment did
not occur in this study.
Discussion
PC is resistant to chemotherapy and poor prognosis.
A standard chemotherapy treatment was gemcitabine
monotherapy when this study started and the
prognosis of advanced PC was about 7–8mo. One of
the reasons of chemotherapy resistance is a cachexia.
PC patients often have symptoms such as appetite
loss, body weight loss, and the decrease of perform-
ance status due to cachexia. As a result, the continu-
ation of chemotherapy is often difficult (14). The
control of cachexia seems to be a key in the chemo-
therapy of advanced PC. EPA had been reported to
inhibit cachexia and in addition nutritional support is
also considered to be important in cachexia (6). The
oral supplement in this study is a promising treatment
including EPA, high protein, and energy.
PFS is the same throughout and the early period of
OS curves are not different; however, in the latter
period of OS, the EPA group was better than the gem-
citabine group and 1-year survival of the EPA group
was 35% and that of the gemcitabine group was 19%.
As a reason for that, there seemed to be CRP and
albumin changes. CRP is a marker of cachexia (15)
and albumin is a marker of sarcopenia which is
caused by cachexia (16). In this study, there was low
frequency of CRP elevation with the EPA group.
Moreover, at the time of treatment discontinuation,
the numbers of high albumin and low CRP patients
were higher in the EPA group. This seemed to be
linked to better second-line chemotherapy and better
prognosis. We suppose that it caused the change in
the latter half of OS period. The anti-inflammation
effect of EPA seems to affect the CRP elevation.
Recently, the importance of MENAC (Multimodal-
Exercise, Nutrition and Anti-inflammatory medication
Figure 2. Subgroup analysis for men (OS).
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for Cachexia) was reported (17). Because EPA is one
of the targeted cachexia treatments in the MENAC
trial, our data support the importance of the
MENAC trial.
In the subgroup analyses, male, patients with pancre-
atic body-tail cancer, and patients with low CRP had
good prognosis. These parameters usually are not prog-
nostic factors in PC. The averages of a total EPA-
enriched oral supplement were 122.4 packs in male and
61.5 packs in female (P¼ 0.01). And these were 64.7
packs in pancreatic head cancer and 122.2 packs in
pancreatic body-tail cancer (P¼ 0.01). The reason for
gender differences is based on physiques and the food
intake including oral supplements. And then the reason
for low intake of oral supplements in the pancreatic head
is duodenal stenosis or biliary tract obstruction since the
food intake would decrease due to the difficulty of pas-
sage or the preparation of the endoscopic treatment. The
effect of an EPA-enriched oral supplement may depend
on the volume of EPA and food intake.
Although the patients with high CRP in this study
expected better results, the patients with low CRP
Figure 3. A: Subgroup analysis for body to tail (OS). B: Subgroup analysis for body to head (OS).
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showed better results. It seemed that the effect of an
EPA-enriched oral supplement was the prevention of
the worsening in the nutritional status. The effect of
an EPA-enriched oral supplement is sufficient for low
level of cachexia, but insufficient for high level of
cachexia. Fearon classified cachexia into three classes
such as pre-cachexia, cachexia syndrome, and severe
cachexia (18). An EPA-enriched oral supplement may
play a role in pre-cachexia.
Limitations of this study were as follows: First, due
to this being a small randomized study, attention
Figure 4. A: Subgroup analysis for lower CRP (OS). B: Subgroup analysis for higher CRP (OS).
Table 2. Response rate.
EPA (N¼ 43) Gemcitabine (N¼ 23)
N % N % P-valuea
Complete response 0 (0.0) 0 (0.0)
Partial response 2 (4.7) 2 (8.7)
Stable disease 27 (62.8) 13 (56.5)
Progressive disease 12 (27.9) 6 (26.1)
Not evaluable 2 (4.7) 2 (8.7)
Response rate 2 (4.7) 2 (8.7) 0.606
95% CI [0.6,15.8] [1.1,28.0]
Disease control rate 29 (67.4) 15 (65.2) 1.000
95% CI [51.5,80.9] [42.7,83.6]
CI: confidence interval.
aP-values were calculated with Fisher’s exact test.
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should first be paid to the interpretations of the small
subgroup analyses, and future studies need to take
them into account by stratification. Second, this was
an open-label trial, and we cannot completely rule out
the possibility of intake of an EPA-enriched oral sup-
plement or EPA-containing food in the control arm
that might have weakened the differences. However,
the EPA-enriched oral supplements were obtained
with research funding and distributed to the subjects
and the effect of the intake of Japanese food contain-
ing EPA seemed to be small. Because the EPA content
is reported to be 2–1,400mg/100 g depending on the
part or kind of fish and the EPA volume for most fish
is under 500mg/100 g (19), it is quite difficult to
achieve an intake of 1–2 g EPA every day. Third, in
this study, it was difficult to achieve an intake of two
packs of the total EPA-enriched oral supplement due
to its taste (20) and a feeling of fullness when com-
bined with a normal meal. We may have to consider
more palatable foods for this. Fourth, a recent pancre-
atic enzyme replacement therapy (PERT) has been
reported to be an important factor in the pancreatic
exocrine insufficiency in advanced PC (21). We could
not evaluate to what degree the patients received
PERT. Nevertheless, the exclusion criteria excluded
patients with severe diarrhea. Furthermore, only 17%
of the patients in the control arm had Grade 1–2 diar-
rhea as an adverse event. As a result, the effect of
PERT was small in this trial.
Currently, FOLFIRINOX and gemcitabine plus
nab-paclitaxel are internationally recognized as stand-
ard regimens for the chemotherapy of metastatic PC.
These chemotherapy treatments would result in
increased numbers of adverse reactions compared
with gemcitabine monotherapy. As regards the
patients in this study, it might be difficult for some of
them to receive the combined chemotherapy due to
age and low performance status. Recently, adverse
reactions to combined chemotherapy were reported to
be increased in low albumin patients (22). Thus, the
addition of an EPA-enriched oral supplement would
still be important in recent standard chemotherapy.
In conclusion, an EPA-enriched oral nutritional
supplement with gemcitabine improved 1-year sur-
vival in randomized phase II study. The anti-inflam-
mation effect of EPA seemed to prevent cachexia.
Further investigation would be needed in combination
with FOLFIRINOX and gemcitabine plus
nab-paclitaxel.
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